PDF(Pubmed)
Abstract：
UNASSIGNED: The overall survival of peripheral T-cell lymphoma (PTCL) is dismal. Histone deacetylase (HDAC) inhibitors have exhibited promising treatment outcomes for PTCL patients. Therefore, this work aims to systematically evaluate the treatment outcome and safety profile of HDAC inhibitor-based treatment for untreated and relapsed/refractory (R/R) PTCL patients.
UNASSIGNED: The prospective clinical trials of HDAC inhibitors for the treatment of PTCL were searched on the Web of Science, PubMed, Embase, ClinicalTrials.gov, and Cochrane Library database. The pooled overall response rate, complete response (CR) rate, and partial response rate were measured. The risk of adverse events was evaluated. Moreover, the subgroup analysis was utilized to assess the efficacy among different HDAC inhibitors and efficacy in different PTCL subtypes.
UNASSIGNED: For untreated PTCL, 502 patients in seven studies were involved, and the pooled CR rate was 44% (95% CI, 39-48%). For R/R PTCL patients, there were 16 studies included, and the CR rate was 14% (95% CI, 11-16%). The HDAC inhibitor-based combination therapy exhibited better efficacy when compared with HDAC inhibitor monotherapy for R/R PTCL patients (P = 0.02). In addition, the pooled CR rate was 17% (95% CI, 13-22%), 10% (95% CI, 5-15%), and 10% (95% CI, 5-15%) in the romidepsin, belinostat, and chidamide monotherapy subgroups, respectively. In the R/R angioimmunoblastic T-cell lymphoma subgroup, the pooled ORR was 44% (95% CI, 35-53%), higher than other subtypes. A total of 18 studies were involved in the safety assessment of treatment-related adverse events. Thrombocytopenia and nausea were the most common hematological and non-hematological adverse events, respectively.
UNASSIGNED: This meta-analysis demonstrated that HDAC inhibitors were effective treatment options for untreated and R/R PTCL patients. The combination of HDAC inhibitor and chemotherapy exhibited superior efficacy to HDAC inhibitor monotherapy in the R/R PTCL setting. Additionally, HDAC inhibitor-based therapy had higher efficacy in angioimmunoblastic T-cell lymphoma patients than that in other subtypes.
UNASSIGNED: The prospective clinical trials of HDAC inhibitors for the treatment of PTCL were searched on the Web of Science, PubMed, Embase, ClinicalTrials.gov, and Cochrane Library database. The pooled overall response rate, complete response (CR) rate, and partial response rate were measured. The risk of adverse events was evaluated. Moreover, the subgroup analysis was utilized to assess the efficacy among different HDAC inhibitors and efficacy in different PTCL subtypes.
UNASSIGNED: For untreated PTCL, 502 patients in seven studies were involved, and the pooled CR rate was 44% (95% CI, 39-48%). For R/R PTCL patients, there were 16 studies included, and the CR rate was 14% (95% CI, 11-16%). The HDAC inhibitor-based combination therapy exhibited better efficacy when compared with HDAC inhibitor monotherapy for R/R PTCL patients (P = 0.02). In addition, the pooled CR rate was 17% (95% CI, 13-22%), 10% (95% CI, 5-15%), and 10% (95% CI, 5-15%) in the romidepsin, belinostat, and chidamide monotherapy subgroups, respectively. In the R/R angioimmunoblastic T-cell lymphoma subgroup, the pooled ORR was 44% (95% CI, 35-53%), higher than other subtypes. A total of 18 studies were involved in the safety assessment of treatment-related adverse events. Thrombocytopenia and nausea were the most common hematological and non-hematological adverse events, respectively.
UNASSIGNED: This meta-analysis demonstrated that HDAC inhibitors were effective treatment options for untreated and R/R PTCL patients. The combination of HDAC inhibitor and chemotherapy exhibited superior efficacy to HDAC inhibitor monotherapy in the R/R PTCL setting. Additionally, HDAC inhibitor-based therapy had higher efficacy in angioimmunoblastic T-cell lymphoma patients than that in other subtypes.
摘要：
■外周T细胞淋巴瘤（PTCL）的总生存期令人沮丧。组蛋白去乙酰化酶（HDAC）抑制剂对PTCL患者具有良好的治疗效果。因此,这项工作旨在系统评估基于HDAC抑制剂的治疗对未治疗和复发/难治性(R/R)PTCL患者的治疗结果和安全性.
■在WebofScience上搜索了HDAC抑制剂治疗PTCL的前瞻性临床试验，PubMed,Embase,ClinicalTrials.gov,和Cochrane图书馆数据库。汇总的总体反应率，完全反应（CR）率，并测量部分反应率。评估不良事件的风险。此外，亚组分析用于评估不同HDAC抑制剂的疗效和不同PTCL亚型的疗效.
■对于未经处理的PTCL，参与了7项研究的502名患者，合并CR率为44%(95%CI，39-48%)。对于R/RPTCL患者，包括16项研究，CR率为14%(95%CI,11-16%)。与HDAC抑制剂单一疗法相比，基于HDAC抑制剂的联合疗法对R/RPTCL患者表现出更好的疗效（P=0.02）。此外,合并CR率为17%(95%CI，13-22%)，10%（95%CI，5-15%），和10%（95%CI，5-15%）的罗米地辛，belinostat,和西达本胺单药治疗亚组，分别。在R/R血管免疫母细胞性T细胞淋巴瘤亚组中，合并的ORR为44%（95%CI，35-53%），高于其他亚型。共有18项研究参与治疗相关不良事件的安全性评估。血小板减少和恶心是最常见的血液学和非血液学不良事件。分别。
■这项荟萃分析表明，HDAC抑制剂是未经治疗和R/RPTCL患者的有效治疗选择。在R/RPTCL设置中，HDAC抑制剂和化学疗法的组合显示出优于HDAC抑制剂单一疗法的疗效。此外,基于HDAC抑制剂的治疗在血管免疫母细胞性T细胞淋巴瘤患者中的疗效高于其他亚型。
■在WebofScience上搜索了HDAC抑制剂治疗PTCL的前瞻性临床试验，PubMed,Embase,ClinicalTrials.gov,和Cochrane图书馆数据库。汇总的总体反应率，完全反应（CR）率，并测量部分反应率。评估不良事件的风险。此外，亚组分析用于评估不同HDAC抑制剂的疗效和不同PTCL亚型的疗效.
■对于未经处理的PTCL，参与了7项研究的502名患者，合并CR率为44%(95%CI，39-48%)。对于R/RPTCL患者，包括16项研究，CR率为14%(95%CI,11-16%)。与HDAC抑制剂单一疗法相比，基于HDAC抑制剂的联合疗法对R/RPTCL患者表现出更好的疗效（P=0.02）。此外,合并CR率为17%(95%CI，13-22%)，10%（95%CI，5-15%），和10%（95%CI，5-15%）的罗米地辛，belinostat,和西达本胺单药治疗亚组，分别。在R/R血管免疫母细胞性T细胞淋巴瘤亚组中，合并的ORR为44%（95%CI，35-53%），高于其他亚型。共有18项研究参与治疗相关不良事件的安全性评估。血小板减少和恶心是最常见的血液学和非血液学不良事件。分别。
■这项荟萃分析表明，HDAC抑制剂是未经治疗和R/RPTCL患者的有效治疗选择。在R/RPTCL设置中，HDAC抑制剂和化学疗法的组合显示出优于HDAC抑制剂单一疗法的疗效。此外,基于HDAC抑制剂的治疗在血管免疫母细胞性T细胞淋巴瘤患者中的疗效高于其他亚型。
